COMPANY

Noctrix Health, Inc.

HQ: Pleasanton, CA source · noctrixhealth.com ↗ · West Coast

Status: Acquired, now part of ResMed · How status works

New owner: Acquired by ResMed (closed on or before 2026-06-01) · source (Jun 1, 2026) · Ownership changes

Also known as Noctrix Health · 10 open jobs · last seen Oct 23, 2026 · 15 sources

At Noctrix Health, Inc we are developing the generation of clinically validated wearable therapeutics for the management of chronic neurological disorders. From company website Source · Oct 12, 2026

Keywords: neurology wearables Restless Legs Syndrome NTX100 Neuromodulation System - Active NTX100 Neuromodulation System - Sham NTX100 Noninvasive Peripheral Nerve Stimulation NTX100 Neuromodulation System

Profile checked Oct 10, 2026

10Open jobs 9Trials (company is sponsor)5NIH grants

Hiring

Title	Location (from posting)	Employer posted	First seen
Patient Activation Specialist (Fargo, North Dakota)	Fargo, North Dakota	Oct 22, 2026	Oct 23, 2026
Senior Clinical Research Scientist	Pleasanton, CA	Oct 13, 2026	Oct 14, 2026
Director, Supply Chain & Operations	Pleasanton, CA	Sep 22, 2026	Oct 5, 2026
Payments Associate	Pleasanton, CA	Sep 15, 2026	Oct 5, 2026
Manager, Regulatory Affairs	Pleasanton, CA	Aug 13, 2026	Oct 5, 2026

See all 10 jobs

Funding and NIH signals

NIH award NIH awarded $1.32M (SBIR Phase II 5R44NS117294-05, continuation, notice May 19, 2026); since then posted 11 roles. NIH RePORTER 5R44NS117294-05 (May 19, 2026)
Evidence (1 event)
- May 19, 2026 · NIH RePORTER 5R44NS117294-05
  Organization: NOCTRIX HEALTH, INC; City/State: Pleasanton, CA; Project number: 5R44NS117294-05; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-05-19; FY total cost (award amount): 1324304; Administering IC: National Institute of Neurological Disorders and Stroke; Project title: Developing closed-loop tonic motor activation therapy for treatment of refractory restless legs syndrome; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Oct 5, 2026 Board tracked Radar started tracking this company’s job board (10 open jobs at last check). source ↗
Jun 8, 2026 Trial start Not phased (device or behavioral study): Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) source ↗
2026-04 Trial start Not phased (device or behavioral study): Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation source ↗
Mar 11, 2025 Trial start Not phased (device or behavioral study): Response to an Investigational Device in Patients With Restless Legs Syndrome source ↗
Nov 15, 2023 Trial start —: A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLS source ↗
Mar 8, 2022 Trial start Not phased (device or behavioral study): Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS source ↗
Dec 20, 2021 Trial start Not phased (device or behavioral study): Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS source ↗
May 6, 2021 Trial start Not phased (device or behavioral study): Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study) source ↗
Apr 6, 2021 Trial start Not phased (device or behavioral study): Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction source ↗
Jul 14, 2019 Trial start Not phased (device or behavioral study): Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome source ↗

Upcoming milestones

2026-12 (ESTIMATED) · Not phased · Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) · NCT07675109
2027-01 (ESTIMATED) · Not phased · Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation · NCT07397247

Estimated primary completion per ClinicalTrials.gov. Dates move.

Open jobs 10

Title	Location (from posting, not HQ)	Employer posted	First seen	Level
Patient Activation Specialist (Fargo, North Dakota)	Fargo, North Dakota	Oct 22, 2026	Oct 23, 2026	Not stated
Senior Clinical Research Scientist	Pleasanton, CA	Oct 13, 2026	Oct 14, 2026	Senior
Director, Supply Chain & Operations	Pleasanton, CA	Sep 22, 2026	Oct 5, 2026	Senior
Payments Associate	Pleasanton, CA	Sep 15, 2026	Oct 5, 2026	Entry
Manager, Regulatory Affairs	Pleasanton, CA	Aug 13, 2026	Oct 5, 2026	Mid
Director, Clinical Affairs	Pleasanton, CA	Aug 13, 2026	Oct 5, 2026	Senior
Patient Access Appeals Case Manager	Remote	Aug 5, 2026	Oct 5, 2026	Mid
Patient Access Case Manager	Remote	Aug 4, 2026	Oct 5, 2026	Mid
Head of Marketing	Pleasanton, CA	Jun 20, 2026	Oct 5, 2026	Executive
Senior Full Stack Software Engineer	Pittsburgh, PA	Jun 16, 2026	Oct 5, 2026	Senior

Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.

Clinical trials (lead sponsor) 9

Record	Title	Phase	Status	Start	Primary completion
NCT07675109	Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS)	Not phased (device or behavioral study)	Recruiting	Jun 8, 2026	2026-12 (estimated)
NCT06076499	A Post-Market Study for Long-Term Effectiveness and Safety of the TOMAC System for RLS	Not listed	Active, not recruiting	Nov 15, 2023	2026-07 (estimated)
NCT07397247	Tonic Motor Activation (TOMAC) Therapy in Patients With Restless Legs Syndrome and Dopaminergic Augmentation	Not phased (device or behavioral study)	Not yet recruiting	2026-04	2027-01 (estimated)
NCT06866132	Response to an Investigational Device in Patients With Restless Legs Syndrome	Not phased (device or behavioral study)	Active, not recruiting	Mar 11, 2025	Aug 4, 2025 (actual)
NCT04874155	Noninvasive Peripheral Nerve Stimulation for Medication-Refractory Primary RLS (The RESTFUL Study)	Not phased (device or behavioral study)	Completed	May 6, 2021	Mar 18, 2022 (actual)
NCT04698343	Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome During Opioid Medication Reduction	Not phased (device or behavioral study)	Completed	Apr 6, 2021	Feb 27, 2023 (actual)
NCT05196828	Extension Study Evaluating NTX100 Neuromodulation System for Medication-Refractory Primary RLS	Not phased (device or behavioral study)	Completed	Dec 20, 2021	Sep 27, 2022 (actual)
NCT05214963	Noninvasive Peripheral Nerve Stimulation for Medication-Naive and Medication-Refractory RLS	Not phased (device or behavioral study)	Completed	Mar 8, 2022	Jul 24, 2023 (actual)
NCT04700683	Noninvasive Peripheral Nerve Stimulation for Restless Legs Syndrome	Not phased (device or behavioral study)	Completed	Jul 14, 2019	Mar 1, 2020 (actual)

NIH awards 5

Annual award amounts. Total $4.6M.

May 19, 2026 NIH award 5R44NS117294-05 FY2026: $1,324,304 awarded for that fiscal year; activity R44 (SBIR); PI CHARLESWORTH, JONATHAN DAVID; recipient as written: NOCTRIX HEALTH, INC, Pleasanton, CA. Developing closed-loop tonic source ↗
May 12, 2025 NIH award 2R44NS117294-04 FY2025: $515,503 awarded for that fiscal year; activity R44 (SBIR); PI CHARLESWORTH, JONATHAN DAVID; recipient as written: NOCTRIX HEALTH, INC, Pleasanton, CA. Developing closed-loop tonic m source ↗
Sep 22, 2022 NIH award 5R44NS117294-03 FY2022: $1,064,334 awarded for that fiscal year; activity R44 (SBIR); PI CHARLESWORTH, JONATHAN DAVID; recipient as written: NOCTRIX HEALTH, INC, Pleasanton, CA. Treatment of Restless Legs S source ↗
May 18, 2021 NIH award 4R44NS117294-02 FY2021: $1,203,447 awarded for that fiscal year; activity R44 (SBIR); PI CHARLESWORTH, JONATHAN DAVID; recipient as written: NOCTRIX HEALTH, INC, Pleasanton, CA. Treatment of Restless Legs S source ↗
Apr 20, 2020 NIH award 1R44NS117294-01 FY2020: $461,490 awarded for that fiscal year; activity R44 (SBIR); PI CHARLESWORTH, JONATHAN DAVID; recipient as written: NOCTRIX HEALTH, INC, Pleasanton, CA. Treatment of Restless Legs Syn source ↗

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

InvestorListed in the portfolio of OrbiMed (captured Oct 12, 2026). portfolio page ↗